Clin Invest Med 2016;39:E48e62
The problem is that zero clinical trials have tested whether this translates to fewer side effects or equivalent weight loss
When you stop the medication, appetite tends to return, and without the pharmacological appetite suppression, a significant portion of lost weight typically comes back unless behavioral habits are strongly maintained
This makes it a promising option for those seeking significant and sustained weight loss
Other combinations of entero-pancreatic hormones, including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA), have progressed to phase 3 trials as obesity treatments, and early data suggest that they may lead to even greater weight loss than tirzepatide [28]
A compounded drug can be prescribed for a patient-specific medical need, but it is not an FDA-approved generic